Insilico Medicine, a clinical-stage company leveraging generative artificial intelligence (AI) for drug discovery and development, has announced promising results for its novel drug, ISM5411, aimed at treating Inflammatory Bowel Disease (IBD). This gut-restricted and PHD-specific inhibitor was
Glioblastoma, an aggressive and often fatal form of brain cancer, has long posed a formidable challenge to medical professionals. With an average lifespan of 12 to 15 months post-diagnosis and a mere 5% survival rate five years after diagnosis, the need for innovative treatments has never been more
Penn Medicine’s Center for Cellular Immunotherapies (CCI) is at the forefront of revolutionizing cancer treatment through CAR (chimeric antigen receptor) T cell therapy. This innovative approach harnesses the power of the patient’s own immune system to target and destroy cancer cells, offering new
Randomized controlled trials (RCTs) are widely recognized as the gold standard for evaluating the efficacy of interventions. In the context of HIV research in Africa, multicenter RCTs are particularly valuable due to the diverse socio-cultural and geographical settings. This scoping review aims to
The landscape of clinical trials is on the brink of a significant transformation, driven by the integration of Real World Data (RWD). By 2025, the use of RWD is expected to revolutionize the way clinical trials are conducted, offering new opportunities for efficiency, accuracy, and patient-centric
Recent advancements in imaging technology have caused a significant shift in how high-risk nonmetastatic hormone-sensitive prostate cancer is staged. Conventional imaging techniques, which have long been the standard, might have significantly underestimated the extent of metastasis in these
